5 November 2019

AMRA’s Abstract Accepted for Poster Presentation and Lightning Talk at ObesityWeek 2019 in Las Vegas

AMRA’s Abstract Accepted for Poster Presentation and Lightning Talk at ObesityWeek 2019 in Las Vegas

LINKÖPING, Sweden; November 5, 2019 – ObesityWeek is the world’s largest obesity-focused conference, which brings researchers, physicians, surgeons, and healthcare professionals together to share and discuss bench-to-bedside innovations.

AMRA’s abstract on a novel method for enabling objective sarcopenia detection across all BMI classes has been accepted for presentation at the 2019 ObesityWeek conference in Las Vegas. Sarcopenia is a common complication in individuals with various diseases and may be predictive of comorbidities and prognosis. AMRA will present recent findings demonstrating the utility of MRI-based muscle composition assessment to detect sarcopenia-related problems and low functional performance in individuals with obesity.

In a study involving 9615 subjects, AMRA evaluated the prevalence of sarcopenia across all BMI classes and quantified fat-free muscle volume and muscle fat infiltration using MRI.  Each participant was sex- and BMI-matched using a virtual control group to estimate individual deviation from expected muscle volume. The clinical value of combining this measure with muscle fat infiltration was assessed through hospital nights, hand grip strength, stair climbing, walking pace, and falls. AMRA’s study revealed that current sarcopenia definitions are BMI-dependent, which limits sarcopenia detection in individuals with obesity where functional performance is low. This highlights the need to adjust for BMI variations when assessing sarcopenia.

AMRA’s method of incorporating virtual control groups enabled proper muscle assessment across all BMI-classes. Furthermore, the combination of fat-free muscle volume and muscle fat infiltration provided a more complete, muscle-specific description linked to function, enabling objective sarcopenia detection.

This study will be discussed in detail through a Lightning Talk today and a poster presentation tomorrow at the Obesity Week conference.

Oral Presentation:

On the Definition of Sarcopenic Obesity – Initial Results From UK Biobank (T-P-3301)

Session: Lightning Talk

Location: Mandalay Bay South Convention Center, Breakers IJ

Date & Time: Tuesday, November 5, 2019 from 10:15-11:45 am

 

Poster Presentation:

On the Definition of Sarcopenic Obesity – Initial Results From UK Biobank (T-P-3301)

Session: Musculoskeletal – TOS Poster Session

Location: Mandalay Bay South Convention Center: Shoreline Exhibit Hall

Date & Time: Wednesday, November 6, 2019 from 12:00– 1:30 pm

 

Attend AMRA’s presentations and connect with our team at Obesity Week to learn more about our research and technology.

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making from clinical research to health and wellness.

Contact

Marie Börjesson
Senior Director, Brand & Marketing
marie.borjesson@amramedical.com

comment

Latest News

language

Meet Us Here